Article Text

Download PDFPDF
Continuous glucose monitoring improved glycaemic control in pregnant women with diabetes and reduced infant macrosomia

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

H R Murphy

Dr H R Murphy, University of Cambridge, Cambridge, UK;


Does continuous glucose monitoring (CGM) improve glycaemic control in pregnant women with diabetes and reduce infant macrosomia?



randomised controlled trial. Current Controlled Trials ISRCTN84461581.





Follow-up period:

to delivery.


2 diabetes antenatal clinics in the UK.


71 pregnant women (mean age 31 y, mean gestational age 9 wks) who had type 1 diabetes (65% of women) or type 2 diabetes (35%) treated with insulin.


CGM plus standard antenatal care (n = 38) or standard care alone (n = 33). CGM was done every 4–6 weeks until 32 weeks of gestation. A subcutaneous sensor, attached to a portable monitor, was implanted by a nurse into the woman’s hip and worn for 5–7 days. The device recorded average tissue glucose concentrations every 5 minutes, but results …

View Full Text


  • Source of funding: Ipswich Diabetes Centre Charity Research Fund; study equipment donated by Medtronic UK.